Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus
Andreas B Petersen,1 Mikkel Christensen1,21Department of Clinical Pharmacology, Bispebjerg Hospital, Copenhagen, Denmark; 2Diabetes Research Division, Department of Internal Medicine, Gentofte Hospital, Copenhagen, DenmarkAbstract: The glucagon-like peptide (GLP)-1 receptor agonist lixisenatide (Lyx...
Enregistré dans:
Auteurs principaux: | Petersen AB, Christensen M |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2013
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/7b095839cdb5437283aae518cecf7f0c |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes
par: Hoimark L, et autres
Publié: (2012) -
Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
par: Jason Seewoodhary, et autres
Publié: (2010) -
Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes
par: Mann KV, et autres
Publié: (2014) -
Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study
par: Saunders WB, et autres
Publié: (2016) -
Emerging utility of once-weekly exenatide in patients with type 2 diabetes
par: Goud A, et autres
Publié: (2015)